Octagon Capital Advisors LP
Octagon Capital Advisors LP reported 26 holdings worth US$751M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Octagon Capital Advisors LP reported 26 holdings worth US$751M as of Sep 30, 2026. Largest: Dianthus Therapeutics, Inc., Abivax SA and Definium Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 26
- Value as reported
- US$751M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Dianthus Therapeutics, Inc. | 1.69M | US$149M | 19.8% |
| Abivax SA | 993K | US$98.3M | 13.1% |
| Definium Therapeutics, Inc. | 2.51M | US$95.6M | 12.7% |
| Cogent Biosciences, Inc. | 2.35M | US$75.2M | 10.0% |
| ArriVent BioPharma, Inc. | 2.14M | US$64.8M | 8.6% |
| Taysha Gene Therapies, Inc. | 9.69M | US$47.2M | 6.3% |
| Obsidian Therapeutics, Inc. | 2.41M | US$33.2M | 4.4% |
| Kymera Therapeutics, Inc. | 205K | US$22.9M | 3.1% |
| Disc Medicine, Inc. | 270K | US$17.7M | 2.4% |
| Tango Therapeutics, Inc. | 630K | US$15.7M | 2.1% |
| Xenon Pharmaceuticals Inc. | 420K | US$15.6M | 2.1% |
| Adlai Nortye Group Ltd. | 935K | US$15M | 2.0% |
| Mirum Pharmaceuticals, Inc. | 169K | US$14.5M | 1.9% |
| Aktis Oncology, Inc. | 713K | US$13.9M | 1.8% |
| Palisade Bio, Inc. | 10.3M | US$13.9M | 1.8% |
| BioAge Labs, Inc. | 1.3M | US$9.22M | 1.2% |
| Gyre Therapeutics, Inc. | 954K | US$7M | 0.93% |
| DBV Technologies SA | 574K | US$6.75M | 0.90% |
| Ocular Therapeutix, Inc. | 600K | US$4.6M | 0.61% |
| Trevi Therapeutics, Inc. | 315K | US$4.51M | 0.60% |
| Sensei Biotherapeutics, Inc. | 100K | US$2.97M | 0.40% |
| Precision BioSciences, Inc. | 430K | US$2.69M | 0.36% |
| Unicycive Therapeutics, Inc. | 275K | US$1.29M | 0.17% |
| Gossamer Bio, Inc. | 96,875 | US$1.15M | 0.15% |
| Alumis Inc. | 0 | US$0 | 0.00% |
| Context Therapeutics Inc. | 0 | US$0 | 0.00% |
| Summit Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related